Bridgeway Capital Management, LLC Graybug Vision, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.46 - $1.05 $10,166 - $23,205	-22,100 Reduced 34.53%	41,900 $20,000
Q3 2022 Nov 14, 2022	SELL	$0.93 - $1.18 $46,500 - $59,000	-50,000 Reduced 43.86%	64,000 $60,000
Q2 2022 Aug 15, 2022	SELL	$0.76 - $1.25 $9,120 - $15,000	-12,000 Reduced 9.52%	114,000 $124,000
Q1 2022 May 16, 2022	BUY	$1.13 - $1.93 $40,679 - $69,480	36,000 Added 40.0%	126,000 $155,000
Q3 2021 Nov 15, 2021	BUY	$3.18 - $5.17 $286,200 - $465,300	90,000 New	90,000 $299,000
Q2 2021 Aug 16, 2021	SELL	$3.53 - $6.1 $134,140 - $231,800	-38,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.55 - $35.0 $210,900 - $1.33 Million	38,000 New	38,000 $211,000

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.